WO2000078790A3 - Methods for inhibiting hiv replication - Google Patents
Methods for inhibiting hiv replication Download PDFInfo
- Publication number
- WO2000078790A3 WO2000078790A3 PCT/US2000/016680 US0016680W WO0078790A3 WO 2000078790 A3 WO2000078790 A3 WO 2000078790A3 US 0016680 W US0016680 W US 0016680W WO 0078790 A3 WO0078790 A3 WO 0078790A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- peptides
- reduce
- relates
- inhibit
- Prior art date
Links
- 230000010076 replication Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 abstract 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000035584 blastogenesis Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 231100000617 superantigen Toxicity 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to methods which provide protection against, or reduce the severity, of HIV infections and associated deleterious effects. More particularly it relates to methods of using peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, and/or carrier-conjugates thereof, or antibodies which bind to those peptides, to reduce, inhibit or eliminate stimulation of blastogenesis of monocytes, including T cells, by HIV Nef protein or other superantigen, and to reduce, inhibit or eliminate HIV replication. The invention also relates to methods using isolated and purified nucleic acids encoding the peptides of the invention, or transformed host cells containing those nucleic acids, to produce peptides which are useful in the methods of the invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU57451/00A AU5745100A (en) | 1999-06-18 | 2000-06-16 | Methods for inhibiting hiv replication |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33662799A | 1999-06-18 | 1999-06-18 | |
| US09/336,627 | 1999-06-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2000078790A2 WO2000078790A2 (en) | 2000-12-28 |
| WO2000078790A3 true WO2000078790A3 (en) | 2001-07-05 |
Family
ID=23316949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/016680 WO2000078790A2 (en) | 1999-06-18 | 2000-06-16 | Methods for inhibiting hiv replication |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5745100A (en) |
| WO (1) | WO2000078790A2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998045325A1 (en) * | 1997-04-07 | 1998-10-15 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
-
2000
- 2000-06-16 WO PCT/US2000/016680 patent/WO2000078790A2/en active Application Filing
- 2000-06-16 AU AU57451/00A patent/AU5745100A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998045325A1 (en) * | 1997-04-07 | 1998-10-15 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000078790A2 (en) | 2000-12-28 |
| AU5745100A (en) | 2001-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA91815C2 (en) | Isolated antibody that specifically binds to gdf-8 and use thereof | |
| WO2001047952A3 (en) | Insecticidal proteins from bacillus thuringiensis | |
| EP1288299A3 (en) | TRNA synthetase | |
| NZ602351A (en) | Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use | |
| MXPA04008077A (en) | ANTI-Abeta ANTIBODIES AND THEIR USE. | |
| HUP0004639A2 (en) | Chlamydia protein, gene sequence and uses thereof | |
| WO2001031019A3 (en) | Neisserial antigenic peptides | |
| WO2002057664A3 (en) | Bacillus thuringiensis insecticidal proteins | |
| EP1260587A3 (en) | Tyrosyl tRNA synthetase | |
| AU9315398A (en) | Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response | |
| WO2001048209A3 (en) | Genes identified as required for proliferation of e. coli | |
| WO2002040668A3 (en) | Proteins and dna sequences underlying these proteins used for treating inflammations | |
| Humbard et al. | The N-terminal penultimate residue of 20S proteasome α1 influences its Nα acetylation and protein levels as well as growth rate and stress responses of Haloferax volcanii | |
| WO2002060917A3 (en) | Method to treat hemophilia | |
| Létoffé et al. | Functional characterization of the HasAPF hemophore and its truncated and chimeric variants: determination of a region involved in binding to the hemophore receptor | |
| Zawilak‐Pawlik et al. | HobA–a novel protein involved in initiation of chromosomal replication in Helicobacter pylori | |
| AU6724794A (en) | GRB3-3 gene, its variants and their uses | |
| WO1998011234A3 (en) | Human protein kinases | |
| DE60025704D1 (en) | THE GOODPASTURE ANTIGEN BINDING PROTEIN | |
| WO2000078790A3 (en) | Methods for inhibiting hiv replication | |
| WO2002010336A3 (en) | Mutacin i biosynthesis genes and proteins | |
| AU2002320301A1 (en) | Novel pgc-1 isoforms and uses therefor | |
| Farci et al. | On the S-layer of Thermus thermophilus and the assembling of its main protein SlpA | |
| WO2002077030A3 (en) | Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof | |
| WO2009083968A8 (en) | Novel protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |